{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for phenyl root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2022)
Source URL:
First approved in 2022
Source:
M032
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NADA141526
(2021)
Source URL:
First approved in 2021
Source:
NADA141526
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Verdinexor (KPT-335) is a small-molecule selective inhibitor of nuclear export (SINE). Karyopharm Therapeutics has recently developed first-in-class, novel SINE compounds using molecular modeling to screen a small virtual library of compounds against the NES groove of human exportin-1 (XPO1). These compounds inhibit nuclear-cytoplasmic export by reversibly binding to the cargo recognition site of XPO1 and are orally bioavailable. Verdinexor was shown to potently and selectively inhibit vRNP export and effectively inhibited the replication of various influenza virus A and B strains in vitro, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain. Verdinexor is in development for the treatment of viral indications. Verdinexor is being evaluated for the treatment of lymphomas in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas.
Status:
Possibly Marketed Outside US
Source:
LISSAMINE GREEN
Source URL:
First approved in 2021
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Acid green 50 (Lissamine Green B) is a synthetically produced organic acid dye with two aminophenyl groups. Acid green 50 is extensively used as a food dye and has a medical application as a staining agent. Due to its low toxicity and ability to stain dead and damaged cells the dye (in form of lissamine green strips) was approved as a tool for diagnosis of eye diseases associated with the damage of ocular surface epithelial cells.
Status:
Possibly Marketed Outside US
Source:
RELIVEN by Meroven Llc
(2021)
Source URL:
First approved in 2021
Source:
RELIVEN by Meroven Llc
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
DIROBAN by Merial
Source URL:
First approved in 2017
Source:
ANADA200609
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Melarsomine (melarsomine dihydrochloride) is an organic arsenical chemotherapeutic agent and is a trypanocidal antiparasitic drug. As of 2016 DIROBAN, a generic melarsomine dihydrochloride product, is the only FDA-approved treatment for adult heartworm (Dirofilaria immitis) infection in dogs. It is not approved for treatment in cats, or dogs in late-stage infection. It is marketed by Merial under the trade name Immiticide and is not currently available in the U.S. due to a manufacturing shortage. Sponsored by Anzac Animal Health, LLC and distributed by Zoetis, Inc., DIROBAN is a prescription animal drug supplied as a sterile powder that must be reconstituted with an accompanying sterile water diluent. The exact mode of action on D. immitis is unknown. Post-treatment mortality due to thromboembolism and/or progression of the underlying disease may occur in 10 to 20% of the Class 3 patients treated with DIROBAN.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Teat Dip 7810HP by Surpass Chemical Company, Inc.
(2016)
Source URL:
First approved in 2016
Source:
Teat Dip 7810HP by Surpass Chemical Company, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenyl sodium is organometallic compound. It is used to carry exchange reactions to produce phenylmalonic acid.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Solasulfone (sulphetrone) was used in drug therapy of leprosy. It was also used in a chemotherapy of pulmonary tuberculosis. Sulphetrone has a low toxicity and an antituberculous efficiency approaching that of its parent compound, diaminodiphenylsulphone; it is also curative in infections due to beta-haemolytic streptococci.